A 12 months, open-label, multicenter, randomized, safety. efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of an anti-CD40monoclonal antibody, CFZ533 vs. standard of care control, in adult de novo Liver transplant recipients with a 12 -month additional follow-up

February 04, 2019
Principal Investigator: Nadeen Khoury, MD
kidney, kidney transplant, transplant, donor, recipient, immunosuppression, rejection, antirejection, nephrology, transplant nephrology, medication, conversion, de novo